Sector Update: Health Care Stocks Advance Late Afternoon
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA
Teva Pharmaceuticals USA's Ezetimibe And Simvastatin, Tablet, 10 Mg; 10 Mg, 10 Mg; 20 Mg, 10 Mg; 20 Mg Discontinued
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk Seeks to Block Compounded Victoza
Insider Trades: Walmart, Teva Among Notable Names This Week
Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath
テバ・ファーマシューティカルズ・インダストリーズ(TEVA.US)、取締役が629.4万ドルで普通株28.6万株を売却
米国証券取引委員会(SEC)が12月26日に開示した文書によると、$テバ・ファーマシューティカルズ・インダストリーズ(TEVA.US)$の取締役MIGNONE ROBERTOは、12月20日に1株平均22.0071ドルで普通株28.6万株を売却、合計額は約629.4万ドル。出所:SEC 株式保有報告書とは何かSECは上場会社の内部者 (インサイダー) に対し、株式取引や保有状況の公開を義務付けてい
Teva Pharmaceutical Industries Insider Sold Shares Worth $6,294,031, According to a Recent SEC Filing
Teva Pharmaceutical on Track for Highest Close Since November 2018 -- Data Talk
TEVA Stock Soars to 52-week High, Reaches $22.52
Teva Pharmaceutical Shares Surged for Seven Straight Sessions
FDA Approves First Generic of Novo Nordisk's Victoza
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 A.m. ET on January 29, 2025